undamentalytics Newsletter

Van Tuyl Christopher: insider trades

Officer at Immunovant, Inc. No open-market purchases and 8 sales not made under a pre-set plan, reported from December 19, 2025 to October 9, 2026.

What happened after Van Tuyl Christopher’s sales?

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Van Tuyl Christopher: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 6 +5.3% −6.4% 67% 2 — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Immunovant, Inc. IMVT Chief Legal Officer08December 19, 2025October 9, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 9, 2026October 7, 2026 IMVT Sale $42,544 not yetnot yetnot yet
September 25, 2026September 23, 2026 IMVT Sale $103,481 not yetnot yetnot yet
July 10, 2026July 8, 2026 IMVT Sale $47,702 −25.4%not yetnot yet
June 26, 2026June 26, 2026 IMVT Sale $682,887 −16.6%not yetnot yet
June 22, 2026June 18, 2026 IMVT Sale $93,217 −6.6%not yetnot yet
April 10, 2026April 8, 2026 IMVT Sale $128,247 +44.5%not yetnot yet
March 20, 2026March 18, 2026 IMVT Sale $71,839 +42.1%not yetnot yet
December 19, 2025December 18, 2025 IMVT Sale $290,943 −6.3%not yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Van Tuyl Christopher traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.